SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Thermo Fisher Scientific Inc., a leading U.S.-based medical equipment manufacturer, is reportedly close to finalizing an all-cash acquisition of clinical trial data management company Clario in a deal valued at around $10 billion, according to the Financial Times. While Reuters has not yet confirmed the report, sources suggest the announcement could come as early as Wednesday, provided no last-minute complications arise.
If completed, this would mark Thermo Fisher’s largest acquisition since its $17.4 billion purchase of contract research organization PPD in 2021. The deal underscores Thermo Fisher’s strategic push to expand its footprint in clinical research and digital health data management, sectors that have seen accelerated growth in recent years.
Clario, established in 2021 through the merger of health tech companies ERT and Bioclinica, provides advanced software solutions that help pharmaceutical companies manage and analyze clinical trial data efficiently. The company’s investors include private equity firms Nordic Capital and Astorg. Clario’s technology plays a vital role in streamlining drug development processes, making it an attractive acquisition target amid growing demand for AI-driven healthcare solutions.
Neither Thermo Fisher nor Clario has commented on the reported deal. However, the acquisition aligns with Thermo Fisher’s ongoing strategy of strengthening its portfolio through high-value takeovers. Earlier in 2024, the company announced plans to acquire Solventum’s purification and filtration business for approximately $4.1 billion, further enhancing its capabilities in life sciences and laboratory technologies.
With increasing global demand for laboratory tools and integrated data solutions, Thermo Fisher recently raised its annual profit and revenue forecasts, signaling confidence in its growth trajectory. The potential Clario acquisition would not only expand Thermo Fisher’s reach in clinical research but also reinforce its position as a global leader in healthcare innovation and biotechnology.
